AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37951954
Drug: Dostarlimab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dostarlimab (500 mg)
Trial: 37952114
Drug: NX-13 250
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NX-13 250 mg immediate release (IR)
Trial: 37952114
Drug: NX-13 500
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NX-13 500 mg immediate release (IR)
Trial: 37952114
Drug: NX-13 500
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NX-13 500 mg delayed release (DR)
Trial: 37952114
Drug: NX-13 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NX-13 (all doses)
Trial: 37952131
Drug: Semaglutide (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide (2.4 mg, once-weekly subcutaneous)
Trial: 37952132
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg twice daily (2.5 mg twice daily when indicated)
Trial: 37952133
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (hemoglobin cutoff for transfusion, 7 or 8 g per deciliter)
Trial: 37952133
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (hemoglobin cutoff, <10 g per deciliter)
Trial: 37952254
Drug: lepodisiran 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lepodisiran 4 mg
Trial: 37952254
Drug: lepodisiran 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lepodisiran 12 mg
Trial: 37952254
Drug: lepodisiran 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lepodisiran 32 mg
Trial: 37952254
Drug: lepodisiran 96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lepodisiran 96 mg
Trial: 37952254
Drug: lepodisiran 304
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lepodisiran 304 mg
Trial: 37952254
Drug: lepodisiran 608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lepodisiran 608 mg
Trial: 37952548
Drug: Discontinuous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinuous oxytocin (infusion stopped beyond 6 cm dilation)
Trial: 37952548
Drug: Continuous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous oxytocin (administration continued until delivery)
Trial: 37952550
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tenofovir disoproxil fumarate plus emtricitabine
Trial: 37952982
Drug: Oral azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral azacitidine (Oral-AZA) maintenance
Trial: 37952982
Drug: Injectable hypomethylating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable hypomethylating agents as first subsequent therapy (FST) after Oral-AZA
Trial: 37952982
Drug: Injectable hypomethylating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable hypomethylating agents as first subsequent therapy (FST) after placebo
Trial: 37953814
Drug: Duvelisib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duvelisib (25 mg) for up to 10 days
Trial: 37954037
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus platinum-based chemotherapy (arm A)
Trial: 37954037
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus platinum-based chemotherapy (arm C)
Trial: 37954906
Drug: Pegmolesatide (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegmolesatide (administered once every four weeks)
Trial: 37954906
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (administered one to three times per week)
Trial: 37955005
Drug: Once-daily rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily rhGH
Trial: 37955580
Drug: In utero
RxNorm normalized name: Uteroglobin
DrugBank: Uteroglobin (DB14880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In utero enzyme replacement therapy (IUERT)
Trial: 37955580
Drug: Postnatal enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postnatal enzyme replacement therapy (ERT)
Trial: 37955644
Drug: Intensive Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Insulin Management
Trial: 37955741
Drug: Fedratinib 400
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fedratinib 400 mg orally as intact capsules with a nutritional supplement
Trial: 37955741
Drug: Fedratinib contents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fedratinib contents dispersed in a nutritional supplement via nasogastric tube
Trial: 37955741
Drug: Divided dose
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided dose of 200 mg orally twice daily as intact capsules with a nutritional supplement
Trial: 37955745
Drug: Postnatal steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postnatal steroids (betamethasone, hydrocortisone hemisuccinate)
Trial: 37955745
Drug: No postnatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postnatal steroids (control group)
Trial: 37955825
Drug: Sotrovimab 500
RxNorm normalized name: sotrovimab 500 MG in 8 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotrovimab 500 mg IM dose
Trial: 37956679
Drug: dupilumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dupilumab (100 mg for those weighing ≤30 kg and 200 mg for those weighing more than 30 kg, administered once every 2 weeks by subcutaneous injection)
Trial: 37956679
Drug: placebo (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (during VOYAGE) followed by dupilumab (100 or 200 mg, according to bodyweight, administered once every 2 weeks by subcutaneous injection)
Trial: 37956738
Drug: Pemigatinib 13.5
RxNorm normalized name: pemigatinib 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemigatinib 13.5 mg once daily continuously (CD)
Trial: 37956738
Drug: Pemigatinib 13.5
RxNorm normalized name: pemigatinib 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemigatinib 13.5 mg once daily intermittently (ID)
Trial: 37956792
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence enhanced chronic disease care clinical decision support (eCDC-CDS) integrated within the electronic health record (EHR)
Trial: 37956897
Drug: Warfarin (managed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (managed at INR goal of 2.0-2.5)
Trial: 37956906
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic formula containing Bifidobacterium bifidum, B lactis, Lactobacillus acidophilus, L paracasei, L rhamnosus, and Streptococcus thermophilus, 2 capsules daily for 2 weeks
Trial: 37956906
Drug: Placebo, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 capsules daily for 2 weeks
Trial: 37956906
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic formula
Trial: 37956934
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen treatment (COT)
Trial: 37956984
Drug: Tablet-based intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet-based intervention designed to improve decision-making with respect to health risk behaviors
Trial: 37957175
Drug: Risk-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-directed therapy based on genetics and MRD
Trial: 37957373
Drug: KT-474 (SAR444656)
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: KT-474 (SAR444656) administered as a single dose and then daily for 14 days in healthy volunteers (105 total).
Trial: 37957373
Drug: KT-474 (SAR444656)
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: KT-474 (SAR444656) administered for 28 days in an open-label cohort of 21 patients.
Trial: 37957378
Drug: Neoadjuvant immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immune checkpoint blockade (ICB) treatment
Trial: 37957535
Drug: Mopati intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mopati intervention (treatment partner intervention)
Trial: 37957689
Drug: HPV-DNA testing
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-DNA testing coupled with thermal ablation treatment
Trial: 37957702
Drug: Praziquantel and
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel and Vitamin A on Day 0, followed by SMC drugs on Days 1-3 (treatment group 1)
Trial: 37957702
Drug: Albendazole and
RxNorm normalized name: Albendazole and ivermectin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole and praziquantel on Day 0, followed by SMC drugs on Days 1-3 (treatment group 2)
Trial: 37957702
Drug: SMC drugs
RxNorm normalized name: prosolv SMCC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMC drugs only (control group)
Trial: 37957702
Drug: Praziquantel and
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel and SMC drugs
Trial: 37958331
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg lenalidomide maintenance therapy
Trial: 37958331
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg lenalidomide maintenance therapy
Trial: 37960292
Drug: Miraculin-based food
RxNorm normalized name: food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miraculin-based food supplement
Trial: 37960985
Drug: Sapanisertib (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib (3 mg orally daily for 21 days every 28 days)
Trial: 37961215
Drug: IL13BBζ-CAR T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL13BBζ-CAR T cells delivered weekly into the lateral cerebral ventricles
Trial: 37961683
Drug: Patient-specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific treatment planning using measured optical properties
Trial: 37962072
Drug: Nivolumab at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab at 3 mg/kg every 2 weeks
Trial: 37962077
Drug: Elafibranor (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elafibranor (80 mg once daily)
Trial: 37962202
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (OM Group)
Trial: 37962746
Drug: bardoxolone methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bardoxolone methyl 5-15 mg/day (titrated as tolerated)
Trial: 37962771
Drug: Combination frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination frequency ELF-EMF (5-16-40 Hz)
Trial: 37962876
Drug: Oral health-related
RxNorm normalized name: Healthy Mama Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health-related quality of life measured with the Oral Health Impact Profile (OHIP) instrument
Trial: 37963155
Drug: HemoCue 301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HemoCue 301 with a cut-off of 11.1 g/dL
Trial: 37963155
Drug: Automated Hb
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated Hb with a cut-off of 10.8 g/dL
Trial: 37963723
Drug: Personalised EID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised EID with a target drug trough concentration of 10 µg/mL (EID10)
Trial: 37963723
Drug: Personalised EID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised EID with a target drug trough concentration of 5 µg/mL (EID5)
Trial: 37963723
Drug: Standard interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard interval dosing (SID) of 4 weeks
Trial: 37964096
Drug: Oral Health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Health Assessment Tool (OHAT)
Trial: 37964096
Drug: Functional Oral
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Oral Intake Scale (FOIS)
Trial: 37964379
Drug: Cabiralizumab (anti-CSF1R),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist), and nivolumab (anti-PD-1)
Trial: 37964379
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of anti-CSF1R in murine models
Trial: 37964431
Drug: 3-mg nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-mg nicotine concentration ONP
Trial: 37964431
Drug: 6-mg nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mg nicotine concentration ONP
Trial: 37965250
Drug: Listening to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listening to the Holy Quran recital for 10 minutes twice daily
Trial: 37965307
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of TMEscore with drug susceptibility and immune cell infiltration.
Trial: 37965339
Drug: T cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T cell product specific for CMV and EBV, administered on day +30, total of 25 doses
Trial: 37965376
Drug: Low-intensity shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity shockwave therapy (n=17)
Trial: 37965376
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (n=16)
Trial: 37965466
Drug: Photon-based radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photon-based radiation therapy (XRT)
Trial: 37965771
Drug: Low-dose epinephrine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose epinephrine added to spinal anesthesia
Trial: 37966877
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health intervention 'Olitor' (app usage at least weekly for 3 months)
Trial: 37967050
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy customized for visual symptoms (MBCT-vision)
Trial: 37967058
Drug: Door-to-door delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Door-to-door delivery of oral azithromycin
Trial: 37967058
Drug: Fixed-point delivery
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-point delivery of oral azithromycin
Trial: 37967148
Drug: KCONVAC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCONVAC vaccine (2 doses, 28 days apart)
Trial: 37967326
Drug: 1-dose rVSVΔG-ZEBOV-GP
RxNorm normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-dose rVSVΔG-ZEBOV-GP
Trial: 37967326
Drug: 2-dose rVSVΔG-ZEBOV-GP
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose rVSVΔG-ZEBOV-GP (given on Day 0 and Day 56)
Trial: 37968012
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pantoprazole intravenously daily while mechanically ventilated in the ICU
Trial: 37968012
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo daily while mechanically ventilated in the ICU
Trial: 37968015
Drug: Mean pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean pulmonary artery pressure-cardiac output >5 mm Hg.min/L
Trial: 37968019
Drug: Invasive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive strategy involving early coronary angiography with immediate evaluation for revascularization and optimal medical therapy
Trial: 37968019
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy (optimal medical therapy)
Trial: 37968125
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (SBP target of 110 mmHg to <130 mmHg)
Trial: 37968125
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (SBP target of 130 mmHg to <150 mmHg)
Trial: 37968455
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers treatment
Trial: 37968668
Drug: MenSC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenSC therapy (bilateral intraovarian injection of menstrual blood-derived mesenchymal stromal cells)
Trial: 37968668
Drug: MenSC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenSC therapy
Trial: 37968696
Drug: Post-biopsy anti-HER2
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-biopsy anti-HER2 treatment
Trial: 37968696
Drug: Prior anti-HER2
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prior anti-HER2 treatment
Trial: 37968718
Drug: Low-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose interleukin-2 immunotherapy
Trial: 37968741
Drug: Two-dose AZI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose AZI (biannual azithromycin-MDA)
Trial: 37968741
Drug: Four-dose AZI
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-dose AZI (quarterly azithromycin-MDA)
Trial: 37969395
Drug: apatinib (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apatinib (375 mg, orally, once daily)
Trial: 37969395
Drug: apatinib (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apatinib (375 mg, orally, once daily) plus etoposide (50 mg, orally on days 1-14 of each 21-day cycle)
Trial: 37969640
Drug: Endothelin receptor
RxNorm normalized name: Endothelin receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin receptor blocker (atrasentan)
Trial: 37969640
Drug: Breast cancer
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast cancer patients (before chemotherapy)
Trial: 37969936
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (600 IU daily for 14-16 weeks)
Trial: 37969936
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 capsule daily for 14-16 weeks)
Trial: 37970718
Drug: Gruticibart (anti-FXI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gruticibart (anti-FXI mAb) 2 mg/kg administered through the venous catheter within 24 hours of placement
Trial: 37971194
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg once daily followed by venetoclax ramp-up to 400 mg daily for 22 additional 4-week cycles
Trial: 37971723
Drug: Brolucizumab, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brolucizumab, 6 mg, intravitreal injection every 4 weeks
Trial: 37971723
Drug: Aflibercept, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept, 2 mg, intravitreal injection every 4 weeks
Trial: 37971722
Drug: Nivolumab (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (480 mg intravenously) administered every 28 days for 4 doses
Trial: 37971800
Drug: SparkRx (self-guided,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SparkRx (self-guided, mobile app-based behavioral activation therapy)
Trial: 37971811
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure + Sertraline (PE + sertraline)
Trial: 37972659
Drug: FGFR inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGFR inhibitors (FGFRi) therapy
Trial: 37972659
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MEK inhibition with FGFRi